INmune Bio (NASDAQ:INMB) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of INmune Bio (NASDAQ:INMB) from a hold rating to a sell rating in a report issued on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings upgraded INmune Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 19th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

INmune Bio Price Performance

INmune Bio stock opened at $1.13 on Friday. INmune Bio has a 1-year low of $1.06 and a 1-year high of $2.60. The company’s 50-day moving average is $1.86 and its 200 day moving average is $1.63.

INmune Bio (NASDAQ:INMB) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02).

Institutional Investors Weigh In On INmune Bio

Institutional investors and hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. grew its position in shares of INmune Bio by 64.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 25,246 shares of the company’s stock worth $49,000 after buying an additional 9,850 shares in the last quarter. Ieq Capital LLC purchased a new position in shares of INmune Bio during the second quarter valued at $134,000. BlackRock Inc. bought a new stake in shares of INmune Bio in the second quarter valued at about $508,000. Bank of New York Mellon Corp bought a new stake in shares of INmune Bio in the second quarter valued at about $35,000. Finally, Focus Partners Advisor Solutions LLC bought a new stake in shares of INmune Bio in the second quarter valued at about $71,000. 12.72% of the stock is owned by institutional investors.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage biotechnology company focused on developing treatments that harness and modulate the innate immune system. The company’s research is aimed at addressing diseases in which chronic inflammation or impaired immune function plays a significant role, including cancer, neurodegenerative disorders and certain psychiatric conditions.

Its lead product candidate is XPro, a next-generation tumor necrosis factor inhibitor designed to selectively neutralize soluble TNF while preserving transmembrane TNF signaling.